JP2019521989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521989A5 JP2019521989A5 JP2018565844A JP2018565844A JP2019521989A5 JP 2019521989 A5 JP2019521989 A5 JP 2019521989A5 JP 2018565844 A JP2018565844 A JP 2018565844A JP 2018565844 A JP2018565844 A JP 2018565844A JP 2019521989 A5 JP2019521989 A5 JP 2019521989A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- use according
- administration
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021197648A JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
| JP2023173614A JP7606245B2 (ja) | 2016-06-16 | 2023-10-05 | 眼性新血管形成を低減するための組成物および方法 |
| JP2024213242A JP2025038012A (ja) | 2016-06-16 | 2024-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351231P | 2016-06-16 | 2016-06-16 | |
| US62/351,231 | 2016-06-16 | ||
| PCT/US2017/038012 WO2017218981A2 (en) | 2016-06-16 | 2017-06-16 | Compositions and methods for reducing ocular neovascularization |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197648A Division JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521989A JP2019521989A (ja) | 2019-08-08 |
| JP2019521989A5 true JP2019521989A5 (https=) | 2020-05-28 |
| JP6990667B2 JP6990667B2 (ja) | 2022-02-03 |
Family
ID=60664289
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565844A Active JP6990667B2 (ja) | 2016-06-16 | 2017-06-16 | 眼性新血管形成を低減するための組成物および方法 |
| JP2021197648A Active JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
| JP2023173614A Active JP7606245B2 (ja) | 2016-06-16 | 2023-10-05 | 眼性新血管形成を低減するための組成物および方法 |
| JP2024213242A Pending JP2025038012A (ja) | 2016-06-16 | 2024-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197648A Active JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
| JP2023173614A Active JP7606245B2 (ja) | 2016-06-16 | 2023-10-05 | 眼性新血管形成を低減するための組成物および方法 |
| JP2024213242A Pending JP2025038012A (ja) | 2016-06-16 | 2024-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20190100582A1 (https=) |
| EP (4) | EP4083203B1 (https=) |
| JP (4) | JP6990667B2 (https=) |
| KR (2) | KR20190038536A (https=) |
| AU (1) | AU2017286680B2 (https=) |
| CA (1) | CA3027740A1 (https=) |
| CY (1) | CY1125152T1 (https=) |
| DK (1) | DK3472317T3 (https=) |
| ES (2) | ES2987337T3 (https=) |
| HR (1) | HRP20220612T1 (https=) |
| HU (1) | HUE059424T2 (https=) |
| LT (1) | LT3472317T (https=) |
| PL (1) | PL3472317T3 (https=) |
| PT (1) | PT3472317T (https=) |
| RS (1) | RS63282B1 (https=) |
| SG (1) | SG11201811230RA (https=) |
| SI (1) | SI3472317T1 (https=) |
| SM (1) | SMT202200251T1 (https=) |
| WO (1) | WO2017218981A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3800191B1 (en) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US11021519B2 (en) | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| EP4653536A3 (en) | 2017-03-17 | 2026-02-25 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| EP3727468A4 (en) | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| KR20200136972A (ko) * | 2018-03-30 | 2020-12-08 | 도모키 도도 | 종창 발생 억제형 종양 용해성 바이러스 |
| WO2020219868A1 (en) * | 2019-04-24 | 2020-10-29 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| WO2021046245A1 (en) * | 2019-09-04 | 2021-03-11 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
| WO2021050094A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| CA3147843A1 (en) * | 2019-09-11 | 2021-03-18 | Mehdi Gasmi | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| WO2021071835A1 (en) * | 2019-10-07 | 2021-04-15 | Regenxbio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021108530A1 (en) * | 2019-11-26 | 2021-06-03 | University Of Massachusetts | Recombinant adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
| WO2021163451A1 (en) * | 2020-02-14 | 2021-08-19 | Asklepios Biopharmaceutical, Inc. | Method of treating gene therapy associated toxicity with antibiotics |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN115869425B (zh) * | 2022-12-12 | 2024-08-20 | 北京生物制品研究所有限责任公司 | 一种aav眼用注射液及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2158745C (en) | 1993-03-25 | 2007-06-19 | Richard L. Kendall | Inhibitor of vascular endothelial cell growth factor |
| CN102202694B (zh) * | 2008-10-07 | 2014-03-12 | 博莱科瑞士股份有限公司 | 包含抗-聚合物抗体的靶向构建体和结合它们的脂质体或微泡 |
| US8663624B2 (en) * | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| CN105755044A (zh) * | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| EP3800191B1 (en) * | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| WO2018134168A1 (en) * | 2017-01-17 | 2018-07-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of expressing a polynucleotide of interest in the cone photoreceptors |
-
2017
- 2017-06-16 KR KR1020197001022A patent/KR20190038536A/ko not_active Abandoned
- 2017-06-16 JP JP2018565844A patent/JP6990667B2/ja active Active
- 2017-06-16 PL PL17814228.7T patent/PL3472317T3/pl unknown
- 2017-06-16 ES ES22154859T patent/ES2987337T3/es active Active
- 2017-06-16 HU HUE17814228A patent/HUE059424T2/hu unknown
- 2017-06-16 LT LTEPPCT/US2017/038012T patent/LT3472317T/lt unknown
- 2017-06-16 EP EP22154859.7A patent/EP4083203B1/en active Active
- 2017-06-16 SG SG11201811230RA patent/SG11201811230RA/en unknown
- 2017-06-16 ES ES17814228T patent/ES2916344T3/es active Active
- 2017-06-16 WO PCT/US2017/038012 patent/WO2017218981A2/en not_active Ceased
- 2017-06-16 PT PT178142287T patent/PT3472317T/pt unknown
- 2017-06-16 HR HRP20220612TT patent/HRP20220612T1/hr unknown
- 2017-06-16 CA CA3027740A patent/CA3027740A1/en active Pending
- 2017-06-16 EP EP17814228.7A patent/EP3472317B1/en active Active
- 2017-06-16 EP EP25208689.7A patent/EP4674483A3/en active Pending
- 2017-06-16 KR KR1020227041433A patent/KR102622823B1/ko active Active
- 2017-06-16 RS RS20220484A patent/RS63282B1/sr unknown
- 2017-06-16 DK DK17814228.7T patent/DK3472317T3/da active
- 2017-06-16 AU AU2017286680A patent/AU2017286680B2/en active Active
- 2017-06-16 SI SI201731153T patent/SI3472317T1/sl unknown
- 2017-06-16 EP EP24184081.8A patent/EP4427808A3/en active Pending
- 2017-06-16 SM SM20220251T patent/SMT202200251T1/it unknown
-
2018
- 2018-12-12 US US16/218,350 patent/US20190100582A1/en not_active Abandoned
-
2021
- 2021-12-06 JP JP2021197648A patent/JP7384447B2/ja active Active
-
2022
- 2022-05-12 CY CY20221100331T patent/CY1125152T1/el unknown
- 2022-10-12 US US18/046,112 patent/US20230322911A1/en active Pending
-
2023
- 2023-10-05 JP JP2023173614A patent/JP7606245B2/ja active Active
-
2024
- 2024-12-06 JP JP2024213242A patent/JP2025038012A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521989A5 (https=) | ||
| JP2019521990A5 (https=) | ||
| JP7111924B2 (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| AU2021225178B2 (en) | Treatment of AMD using AAV2 variant with aflibercept | |
| HRP20220612T1 (hr) | Sastavi i metode za smanjenje očne neovaskularizacije | |
| JP2024016207A (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| JP2021503914A5 (https=) | ||
| JP2018517773A (ja) | ＩｇＧＦｃドメインを有する融合タンパク質の安定な液状製剤 | |
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| EP3215123A1 (en) | Methods for treating ocular diseases | |
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| JP2024519629A5 (https=) | ||
| US20120070428A1 (en) | Treatment of vascularized pigment epithelial detachment with anti-vegf therapy | |
| WO2023236964A1 (zh) | 腺相关病毒药物组合物及其用途 | |
| Zeng et al. | “Para-retinal” vector administration into the deep vitreous enhances retinal transgene expression | |
| TW202508610A (zh) | 醫藥組成物及其用途 | |
| Mellen et al. | Gene therapy for neovascular macular degeneration, diabetic retinopathy, and diabetic macular edema | |
| Sundlisæter et al. | Antiangiogenic treatment of ocular diseases | |
| NZ749897A (en) | Treatment of amd using aav2 variant with aflibercept | |
| NZ749897B2 (en) | Treatment of amd using aav2 variant with aflibercept | |
| Dagueta et al. | Evolving knowledge in pharmacologic treatments of age-related macular degeneration | |
| Fenner et al. | When to change course: timing of treatment change in the management of diabetic macular edema | |
| Schwartz et al. | Progressive release of vitreomacular traction with aflibercept | |
| Rafieetary et al. | Gene therapy delivery: Examining the evidence | |
| Rusakevich et al. | Gene therapy for nAMD: The current frontier |